Market Research Logo

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline Review, H2 2016

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Granulomatosis with Polyangiitis (Wegener Polyangiitis) – Pipeline Review, H2 2016, provides an overview of the Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology) pipeline landscape.

Wegener Polyangiitis is an uncommon disorder that causes inflammation of blood vessels. This inflammation restricts blood flow to various organs. Signs and symptoms include constantly runny nose, nose bleeds, ear infections, cough, chest pain, skin sores and fever. Predisposing factor includes age. Treatment includes immunosuppressive and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Granulomatosis with Polyangiitis (Wegener Polyangiitis) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Granulomatosis with Polyangiitis (Wegener Polyangiitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, IND/CTA Filed, Preclinical and Unknown stages are 1, 2, 2, 1, 4 and 1 respectively.

Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Granulomatosis with Polyangiitis (Wegener Polyangiitis) Overview
Therapeutics Development
Pipeline Products for Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Overview
Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Therapeutics under Development by Companies
Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Products under Development by Companies
Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Companies Involved in Therapeutics Development
Bionovis SA
Bristol-Myers Squibb Company
ChemoCentryx Inc
Coherus BioSciences Inc
Genor BioPharma Co Ltd
GlaxoSmithKline Plc
Iltoo Pharma
Panacea Biotec Ltd
Sandoz International GmbH
The International Biotechnology Center (IBC) Generium
Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
abatacept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aldesleukin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avacopan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
belimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Dormant Projects
Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Discontinued Products
Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Product Development Milestones
Featured News & Press Releases
Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Granulomatosis with Polyangiitis (Wegener Polyangiitis), H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline by Bionovis SA, H2 2016
Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline by Bristol-Myers Squibb Company, H2 2016
Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline by ChemoCentryx Inc, H2 2016
Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline by Coherus BioSciences Inc, H2 2016
Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline by Genor BioPharma Co Ltd, H2 2016
Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline by GlaxoSmithKline Plc, H2 2016
Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline by Iltoo Pharma, H2 2016
Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline by Panacea Biotec Ltd, H2 2016
Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline by Sandoz International GmbH, H2 2016
Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Dormant Projects, H2 2016
Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Granulomatosis with Polyangiitis (Wegener Polyangiitis), H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report